

Drug and Therapeutics Committee – Minutes

Date / Time	11 th May 2023
Venue	MS Teams
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, Formulary HUTH
Quorate: Yes / No	Yes

Prof A Morice, Chair, Professor of Respiratory Medicine
Miss J Morgan, Professional Secretary, Principal Pharmacist – Formulary HUTH
Luke Storr – Senior Pharmacy Technician, Formulary HUTH
Mr K McCorry, Medicines Optimisation Pharmacist, NECS
Dr O Ogunbambi, Consultant Rheumatologist, HUTH
Dr S Raise, GP Prescribing Lead, East Riding
Prof M Lind, Vice Chair, Professor of Oncology, HUTH
Dr A Ramirez, Deputy Chief Pharmacist, HUTH

Apologies

Dr A Samson, Consultant Infectious Diseases, HUTH
Dr H Klonin, Consultant Paediatrician, HUTH
Ms J Goode, Chief Pharmacist, HUTH

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
23.05.01	Apologies	As Above.					
23.05.02	Declarations of Interest	None					
23.05.03	Minutes of the previous meeting	Accepted as true record					
23.05.04	Action Tracker	<p>Hydroxychloroquine in RA New action: JM to discuss with relevant business managers Update: August 2022 – to escalate via PE&CE Update: September 2022 – escalated via PE&CE Update: November 2022 – going to December PE&CE Update: December 2022- going to December PE&CE Update: February 2023 – JM to follow up with Sam Coulbeck Update: April 2023 – JM to complete new escalation form from this meeting date</p> <p>ARIA forms – Zoledronic acid JM to write trust guidance in conjunction with DME pharmacy team Update: December 2022 – to discuss with Matthew Heppel Update February 2023 – JM has received guidance from Matthew Heppel, ready to present at next meeting. Update April 2023 – on agenda for next meeting (deferred today)</p> <p>Clinical guidelines – Biologics and small molecules for IBD JM to meet with SS (with surgical team pharmacists) to work on updated guidance and discuss audit Update February 2023 – guideline on agenda, approved and for health group and gastroenterology governance JG to ensure new pharmacy service to IMIC is set up</p>	Ongoing	Re-submit to PE&CE	JM	5/23	
			Ongoing	On agenda	JM	5/23	
			Ongoing		JM		5/22
					JG	6/23	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>Update February 2023 – when guideline approved by health group</p> <p>Update April 2023- guideline on agenda at next health group governance</p> <p>New action: Add guidance to agenda when updated</p> <p>Update February 2023 on agenda</p> <p>New action Sept 2022: Present audit of ustekinumab</p> <p>Update April 2023: JM to discuss with Sarah Westerhold (SHG lead pharmacist).</p> <p>Update May 2023: JM discussed data – 56 patients audited, 53 patients complied with licensed doses of 8-12 weeks and 3 patients with more frequent dosing (100% of these patients had an in date IFR). Audit report to be presented when fully approved</p> <p>Terms of reference update</p> <p>JM to contact Andy Lockwood regarding patient representation on D&TC</p> <p>December update: - JM to chase Andy Lockwood as no response received</p> <p>Update February 2023 – JM has been in touch with Andy Lockwood, original email missed, he will get back to us once he has found someone willing to join. Await response</p> <p>New Product Requests</p> <p>ML to discuss Actimorph replacing Sevredol on formulary with palliative care. JM has contacted Elaine Bowland and taken to APC for classification.</p> <p>New Product Requests</p> <p>AM to write to applicants</p> <p>New Product Requests</p> <p>JM/LS to update formulary</p> <p>New Product Requests</p> <p>JM to add aprotinin audit to agenda in 6 months time</p> <p>Any other business</p> <p>JM to discuss upadacitinib £1 per pack scheme with AR for CD. And organise patients to transfer over to from</p>					
					JM		3/23
					JM	9/23	
			Ongoing	Sent to PE&CE	JM	3/23	
			Action complete		ML		5/23
			Action complete		AM		5/23
			Action complete		JM/LS		5/23
					JM	12/23	
			Action		JM	5/23	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		compassionate use scheme as needed.	complete				
23.05.05	New Product Requests	<p><i>New Product Requests</i></p> <p><i>a) Hydrocortisone MR (Dr Matthews)</i> JM presented this application from the paediatric endocrinology team for modified release hydrocortisone that is licensed from age of 12 years and designed to mimic circadian rhythm of cortisol. Evidence provided showed improved metabolic outcomes compared to multiple times a day immediate release preparations. Concerns were raised around transition to adult services if paediatric approval recommended. AM to contact adult services (Prof Sathyapalan) to discuss transitional care and requirement for further adult services to have access to formulation.</p> <p><i>b) Cefiderocol (L. Cullen/department of infection)</i> The committee had previously received 2 chairs approval requests for this antibiotic. The department of infection had requested addition to formulary in line with the NHS England blueteq form and NICE Antimicrobial health technology evaluation guidance. To add to formulary as restricted antibiotic on Department of Infection advice only</p> <p><i>c) Finerinone (Prof Bhandari)- TA877</i> Approved in line with TA</p> <p><i>d) Eptinezumab (Prof Ahmed)- TA871</i> Approved in line with TA</p> <p><i>ARIA FORMs</i></p> <p><i>e) Trifluridine-Tipiracil - TA852</i></p> <p><i>f) Regorafenib - TA866</i></p> <p><i>g) Lenvatinib - TA858,TA498,TA535</i></p> <p><i>h) Zanubrutinib – TA833</i></p> <p><i>Line Extension</i></p> <p><i>i) Budesonide foam enema</i> Line extension in addition to prednisolone foam enema, which is more cost effective within both primary and secondary care.</p>	<p>a) Approved in HUTH</p> <p>b) Approved subject to blueteq</p> <p>c) Approved</p> <p>d) Approved HUTH only</p> <p>e) Approved</p> <p>f) Approved</p> <p>g) Approved</p> <p>h) Approved</p> <p>i) Approved</p>	AM to write applicants LS/JM to update formulary			

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		DIETETIC REQUESTS Nil this month					
23.05.06	Supply issues	Nil this month					
23.05.07	NICE guidance	<p>Feb 23</p> <ul style="list-style-type: none"> • TA867 Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) • TA869 Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) • TA868 Vutrisiran for treating hereditary transthyretin-related amyloidosis • CG181 Cardiovascular disease: risk assessment and reduction, including lipid modification (update) • TA865 Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma • TA866 Regorafenib for previously treated metastatic colorectal cancer • NG231 Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management • TA861 Upadacitinib for treating active non-radiographic axial spondyloarthritis • TA862 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments • TA864 Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted • TA863 Somatrogen for treating growth disturbance in children and young people aged 3 years and over • TA870 Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma • TA872 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies • HST22 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene 	<p>Terminated appraisal Terminated appraisal</p> <p>Not HUTH</p> <p>Nil for D&TC</p> <p>On formulary</p> <p>On agenda</p> <p>Nil for D&TC</p> <p>On formulary</p> <p>Update names on formulary</p> <p>On formulary</p> <p>On formulary</p> <p>On formulary</p> <p>On formulary</p> <p>Not HUTH</p> <p>Not HUTH</p>	<p>No action required No action required</p> <p>Add to back of formulary No action required Check for ARIA</p> <p>No action required</p> <p>No action required No action required</p> <p>Check for Aria form and update formulary No action required</p> <p>Update formulary with TA Check for Aria form</p> <p>Add to back of formulary</p> <p>Add to back of formulary</p>	<p>LS</p> <p>JM</p> <p>JM/LS</p> <p>LS</p> <p>JM</p> <p>LS</p> <p>LS</p>	<p>6/23</p> <p>6/23</p> <p>6/23</p> <p>6/23</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>March 23</p> <ul style="list-style-type: none"> TA874 Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma TA873 Cannabidiol for treating seizures caused by tuberous sclerosis complex TA871 Eptinezumab for preventing migraine TA875 Semaglutide for managing overweight and obesity NG122 Lung cancer: diagnosis and management TA876 Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer TA877 Finerenone for treating chronic kidney disease in type 2 diabetes NG191 COVID-19 rapid guideline: managing COVID-19 <p>April 23</p> <ul style="list-style-type: none"> TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 NG101 Early and locally advanced breast cancer: diagnosis and management TA879 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) NG133 Hypertension in pregnancy: diagnosis and management HST25 Lumasiran for treating primary hyperoxaluria type 1 HST26 Eladocagene exuparovec for treating aromatic L-amino acid decarboxylase deficiency HST15 Onasemnogene abeparovec for treating spinal muscular atrophy HST24 Onasemnogene abeparovec for treating presymptomatic spinal muscular atrophy TA880 Tezepelumab for treating severe asthma CG104 Metastatic malignant disease of unknown primary origin in adults: diagnosis and management 	<p>On formulary</p> <p>On formulary</p> <p>On agenda</p> <p>No launch date</p> <p>Nil for D&TC</p> <p>On formulary</p> <p>On agenda</p> <p>Nil for D&TC</p> <p>Not on formulary</p> <p>Nil for D&TC</p> <p>Terminated appraisal</p> <p>Nil for D&TC</p> <p>Not HUTH</p> <p>Not HUTH</p> <p>Not HUTH</p> <p>Not HUTH</p> <p>Previously discussed</p> <p>Nil for D&TC</p>	<p>Check for ARIA</p> <p>JM to check with Dr Ming about pts</p> <p>No action required</p> <p>Review when launched</p> <p>No action required</p> <p>Check for Aria</p> <p>No action required</p> <p>No action required</p> <p>Update formulary</p> <p>No action required</p> <p>No action required</p> <p>Add to back of formulary</p> <p>Add to back of formulary</p> <p>Add to back of formulary</p> <p>Add to back of formulary</p> <p>Update formulary</p> <p>No action required</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>LS</p> <p>LS</p> <p>LS</p> <p>LS</p>	<p>6/23</p> <p>6/23</p> <p>6/23</p> <p>6/23</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
23.05.08	MHRA Drug safety update –	<ul style="list-style-type: none"> • Feb 23 • Mar 23 • Apr 23 	Update formulary	Remove pholcodine and add codeine linctus to formulary	LS	6/23	
23.05.09	Minutes of the Safe Medication Practice Committee –	<ul style="list-style-type: none"> • Jan 23 	For info only				
23.05.10	Minutes from the Humber Area Prescribing Committee –	<ul style="list-style-type: none"> • Dec 22 • Feb 23 • Mar 23 • Apr 23 	For info only				
23.05.11	Regional Medicines Optimisation Committee	Nil this month					
23.05.12	Clinical guidelines	<p>a) Zoledronic acid guideline New guidance that has been to relevant speciality governance and health group governances. Including information to support safe discharge in patients who have received zoledronic acid as inpatients.</p> <p>b) Electrolyte guidance Updated guidance. OO raised dissemination of guidance particularly to junior doctors. To discuss with author.</p>	<p>a) Approved b) Approved</p>	b) Look at Pattie banner for trust info and to contact medical education			
23.05.13	Annual report	<ul style="list-style-type: none"> • D&T attendance 22/23 • D&T New Product Requests 22/23 	For info only				
23.05.14	Correspondence received	Nil this month					
23.05.15	Chairs approvals	<ul style="list-style-type: none"> • Docetaxel ovarian cancer (Dr Bozas) 	Approved	Add to chairs	LS	6/23	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
				approval database			
23.05.16	Issues to escalate to Patient Safety and Clinical Effectiveness	Nil this month					
23.05.17	Any other business	Rheumatology guidance (raised in action tracker) KMc raised rheumatology pathways request for the update to these pathways which has been on HERPC action tracker to be added to D&TC action tracker.	Approved	Add to action tracker	OO	9/23	
	Date and time of next meeting	8 th June Thursday 8.15am 2023 Microsoft Teams / Alderson House HRI					